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Background: Bombax ceiba Linn., commonly called as Semal, is used in various gastro-intestinal disturbances. It
contains Lupeol which inhibits PTP-1B, adipogenesis, TG synthesis and accumulation of lipids in adipocytes and
adipokines whereas the flavonoids isolated from B. ceiba has FAS inhibitory activity. The present study was aimed to
investigate ameliorative potential of Bombax ceiba to experimental obesity in Wistar rats, and its possible
mechanism of action.
Methods: Male Wistar albino rats weighing 180-220 g were employed in present study. Experimental obesity was
induced by feeding high fat diet for 10 weeks. Methanolic extract of B. ceiba extract 100, 200 and 400 mg/kg and
Gemfibrozil 50 mg/kg as standard drug were given orally from 7th to 10th week.
Results: Induction with HFD for 10 weeks caused significant (p < 0.05) increase in % body wt, BMI, LEE indices;
serum glucose, triglyceride, LDL, VLDL, cholesterol, free fatty acid, ALT, AST; tissue TBARS, nitrate/nitrite levels;
different fat pads and relative liver weight; and significant decrease in food intake (g and kcal), serum HDL and
tissue glutathione levels in HFD control rats. Treatment with B. ceiba extract and Gemfibrozil significantly attenuated
these HFD induced changes, as compared to HFD control. The effect of B. ceiba 200 and 400 mg/kg was more
pronounced in comparison to Gemfibrozil.
Conclusion: On the basis of results obtained, it may be concluded that the methanolic extract of stem bark of
Bombax ceiba has significant ameliorative potential against HFD induced obesity in rats, possibly through
modulation of FAS and PTP-1B signaling due to the presence of flavonoids and lupeol.
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Obesity is one of the leading causes of death worldwide
[1] and characterized by excess body fat accumulation
[2]. It is a chronic disorder with complex interaction be-
tween genetic and environmental factors and occurs due to
increased intake of high fat and energy food with decreased
energy expenditure. Endogenous involvement of leptin, in-
sulin, ghrelin, CCK (cholecystokinin), NPY (neuropeptide
Y), GLP-1 (glycogen like peptide 1) and PTP-1B (protein
tyrosine phosphate-1B) signaling has potential effect on
food intake and energy expenditure [3]. The stimulation* Correspondence: rohit_pharm@yahoo.co.in
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reproduction in any medium, provided the orof PTP-1B also modulates insulin, leptin and integrin sig-
naling, and thereby stimulates fatty acid synthase (FAS)
activity and results obesity [4,5]. According to Ayurveda,
vitiations in three body humours i.e. tridoshas (vata, pitta
and kapha) is characterized by altered body functions like
metabolism, digestion, appetite and thus precipitates
obesity [6]. The clinical claims revealed that the obesity
is caused due to genetic predisposition and improper
life style.
The traditional system of medicine has incorporated
use of medicinal plant drugs or formulation for the pre-
vention of obesity. Bombax ceiba Linn., belongs to family
Malvaceae, commonly called as semal, shimbal (in hindi)
and red silk cotton tree (in english) [7]. The stem bark is
reported to contain lupeol, shamimicin, flavonoids, glycoside,td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and lactone-7-methyl ether [8,9]. Shamimin (C-flavonol
glucoside) isolated from B. ceiba methanolic extract showed
significant hypotensive and hypoglycaemic properties and
was found to be safe in rodents [9]. Mangiferin obtained
from methanolic extract of B. ceiba leaves demonstrated
strong antioxidant and hepatoprotective activities [10].
Ethno-pharmacologically, it is used to treat diarrhea, dys-
entery, digestive disturbances, diabetes [11] and improves
digestion (Jain, 1996). In ayurveda, B. ceiba is generally rec-
ommended to use in vitiated conditions of vata, pitta and
kapha and removes pitta and kappa [12]. It has a potent
free radical scavenging [13], anti-inflammatory and he-
patoprotective activities [8,14]. The flavonoids isolated
from B. ceiba have a potent FAS inhibitory activity [15].
Lupeol, found in B. ceiba inhibits PTP-1B, adipogenesis,
TG synthesis and accumulation of lipids in adipocytes
and adipokines [16].
On the basis of literature available, we hypothesized to
investigate the possible anti-obesity potential of Bombax
ceiba in high fat diet-induced experimental obesity, pos-
sibly due to the involvement of FAS and PTP-1B signal-
ing in present study.
Methods
Collection, authentication and extraction of plant material
Bombax ceiba Linn. stem bark was collected from Gwalior,
MP, India, authentified from NISCAR, New Delhi under
consultation with Dr. H.B. Singh, Director and a voucher
specimen of plant drug sample was deposited in institu-
tional herbarium (NISCAIR/RHMD/Consult/-20011-12/
1758/58). Stem bark was shade dried, coarsely powdered
and stored in air tight container till further use. The litera-
ture revealed that the phytoconstituents isolated from
methanolic extract of B. ceiba have potent biological ef-
ficacies. Therefore, plant drug extraction was made with
soxhlet extractor using methanol as solvent.
Phytochemical screening
The qualitative phytochemical screening of B. ceiba extract
was carried out for the presence of phytoconstituents
like steroids, terpenoids, anthraquinone glycosides, C-
glycosides, cardiac glycosides, flavonoids, tannins, phen-
olic and carbohydrates [17].
Acute toxicity study
Acute toxicity study of B. ceiba extract was conducted as
per the Organization for Economic Co-operation and
Development (OECD) 423 guidelines: acute toxicity class
method [18] using Wistar albino rats (n = 3). B. ceiba ex-
tract (methanolic) was given orally in doses: 50, 100,
300, 1000 and 2000 mg/kg; suspended in 0.5% CMC so-
lution and the animals were observed for physiological
(body wt, urination, pellet expulsion and salivation),behavioral (irritability, corneal reflex, catatonia, locomo-
tion, convulsion and tremor), biochemical (serum ALT,
AST and glucose) and toxic manifestations and even
mortality, if any, up to 14 days.
Chemicals and reagents
Casein from Modern Dairy, New Karnal, India; cholesterol
from Thomas Baker; and Gemfibrozil from Pfizer, USA
were purchased. The biochemical enzymatic kits were
purchased from Coral Diagnostics Ltd., Mumbai, India.
All other chemicals/reagents used were of analytical grade
and were freshly prepared before use.
Animals
Male, Wistar albino rats, weighing 180-220 g were em-
ployed in present study. They were fed on standard
chow diet (Ashirwad Industries Private Ltd., Ropar,
Punjab, India) and water ad libitum; and maintained at
12-12 h light/dark cycles, temperature 25 ± 2°C and
relative humidity 55 ± 5%. The experimental protocol
was duly been approved by Institutional Animal Ethics
Committee (IAEC) and the experimentations were con-
ducted under the guidelines from Committee for the
purpose of Control and Supervision of Experiments on
Animals (CPCSEA).
High fat diet-induced obesity
Experimental obesity was developed by feeding high fat
diet (Powdered Normal Chow, 365 g; lard, 310 g; casein,
250 g; cholesterol, 10 g; vitamin mix and mineral mix,
60 g; dl-methionine, 03 g; yeast powder, 01 g; and NaCl,
01 g were mixed to prepare 1.0 kg of HFD) [19], to rats
for 10 weeks. The High fat diet contains 5.33 kcal/g
while the normal chow contains 3.80 kcal/g.
Experimental protocol
All animals were divided into different groups each com-
prising six animals (n = 6). The groups were 1). Normal
control receiving vehicle only; 2). HFD control receiving
high fat diet for 10 weeks; 3). Gemfibrozil-50 receiving
gemfibrozil 50 mg/kg as standard; 4), 5), 6) B.C. 100 or
200 or 400 receiving B. ceiba extract 100, 200 and
400 mg/kg respectively. Administration of vehicle, stand-
ard and the plant extracts were done orally from 7th
week to 10 week by suspending in 0.5% CMC solution
as vehicle. After completion of experimental protocol,
pahramcological assessments shall be carried out. Ani-
mals were anaesthetized, blood was collected from retro
orbital plexuses, centrifuged and serum separated for
biochemical estimations. Animals were sacrificed, and
liver and different fat depots were surgically dissected
out. 10% liver homogenate was prepared in 0.1 M Tris
buffer (pH = 7.4) or phosphate buffer (0.1 M, pH = 7.4)
(for glutathione only) for tissue biochemical estimations.
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Assessment of anthropometric parameters
The body mass index (BMI) [20] and Lee index [21]
were assessed as an index of obesity. Body weight and
food intake (g and kcal) were assessed weekly. Weight of
liver and different fat depots: epididymal, retroperitoneal
and mesenteric fat depots, total weights were also esti-
mated [22].
Assessment of serum biochemical parameters
The estimation of serum glucose [23]; total cholesterol
[24]; high density lipoprotein (HDL) [24], low density
lipoprotein LDL-[25]; very low density lipoprotein VLDL
[25]; triglycerides [26]; and ALT, AST [27] were carried
out spectrophotometrically using biochemical enzymatic
kits (Coral Diagnostics Ltd., Mumbai, India).
Serum fatty acid estimation by gas chromatography (GC)
The fatty acid estimation by gas chromatography was
done by modified method of Christie [28]. The fatty acid
was converted to fatty acid ester. For esterification,
300 μl of serum was made upto 3 ml with methanol then
5 drops of concentrated HCl were added. Final step for
esterification was to reflux for 6 hrs. After esterification,
to 500 μl of sample, added 300 μl of distilled water and
toluene, shaked well and centrifuged for 5 minutes. 1 μl
of organic solvent was injected into packed column of
GC. Standard curve of different FAs was determined
using different concentrations: 100-1000 μM of oleic
and palmitic acids. The conditions for GC were: 40-160
(10°C/min), 160-230 (5°C/min), 230-240 (1°C/min), and
stable for 10 min at 240C.
Assessment of tissue biochemical parameters
The tissues were homogenized in 0.1 M tris buffer (pH 7.4)
or 0.1 M phosphate buffer (for glutathione only) using
teflon-glass homogenizer. The 10% liver homogenates were
subjected for following tissue biochemical estimations:
Lipid per oxidation (TBARS)
Lipid per-oxidation was determined by measuring the
amounts of malondialdehyde (MDA) produced primarily
or thiobarbituric acid reactive substances (TBARS), ac-
cording to the modified method of Ohkawa et al [29].
Briefly, 0.2 ml of tissue homogenate, 0.2 ml of 8.1% so-
dium dodecyl sulphate or sodium lauryl sulphate (SDS/
SLS), 1.5 ml of 20% acetic acid and 1.5 ml of 8% TBA
were added. The volume of the mixture was made up to
4 ml with distilled water and then heated at 95°C on a
water bath for 60 min using glass balls as condenser.
After incubation the tubes were cooled to room tem-
perature the upper organic layer was taken and its OD
read at 532 nm against an appropriate blank without the
sample. The levels of lipid peroxides were expressed asnmoles of thiobarbituric acid reactive sub-stances (TBARS)
nmol/mg of liver wt.Reduced glutathione (GSH) [30]
The homogenate was added with equal volume of 20%
trichloroacetic acid (TCA) containing 1 mM EDTA to
precipitate the tissue proteins. The mixture was allowed
to stand for 5 min prior to centrifugation for 10 min at
200 rpm. The supernatant (200 μl) was then transferred
to a new set of test tubes and added 1.8 ml of the Ellman’s
reagent (5, 5′-dithio bis-2-nitrobenzoic acid) (0.1 mM)
was prepared in 0.3 M phosphate buffer with 1% of so-
dium citrate solution). Then all the test tubes make upto
the volume of 2 ml. After completion of the total reaction,
the absorbance of the solutions was estimated at 412 nm
against blank. The level of GSH was expressed as μmol/mg
of liver wt.Nitrite/nitrate level using Greiss reagent [31]
Tissue nitrite/nitrate was estimated using Greiss reagent
which served as an indicator of nitric oxide production.
An amount of 100 μl Greiss reagent (1:1 solution of 1%
sulphanilamide in 5% phosphoric acid and 0.1% napthay-
lamine diamine dihydrochloric acid in water) was added
to 100 μl of supernatant and absorbance was measured
at 542 nm. Nitrite level was expressed as μmol/ mg of
liver wt.Histopathological study
The liver and fat depots were excised out, washed in ice-
cold saline, blotted dry and preserved in 10% formalin
solution. The histopathological study was done using
hematoxylin and eosin stains and observed under micro-
scope to assess changes in liver tissue and size of fat de-
pots [32,33].Statistical analysis
The results were expressed as mean ± standard deviation
(SD) analyzed by one-way and two-way analysis of variance
(ANOVA) followed by Bonferroni’s multiple comparison
test as post hoc analysis. p < 0.05 was considered statistically
significant.Results
Extraction of plant materials
The yield of methanolic extract of B. ceiba Linn stem
bark was found to be 4.69% w/w. Phytochemical screening
of methanolic extract showed the presence of carbohy-
drate, alkaloids, C-glycosides, cardiac glycosides, saponins
glycoside, tannins, terpenoids, steroids and flavonoids
constituents.
Figure 1 Effect of various pharmacological interventions on body weight; Results were expressed as mean ± SD; a = p < 0.05 vs NC,
b = p < 0.05 vs HFD control, c = p < 0.05 vs Gem.50 on respective week.
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B. ceiba extract at the doses of 50, 100, 300, 1000, 2000 mg/kg
showed no significant physiological, behavioral and bio-
chemical alterations and was found to be safe, and pro-
duced no toxic manifestation and mortality in rats. Hence,
the plant extract in doses 100, 200 and 400 mg/kg, p.o. was
selected for further pharmacological investigations.
Effect of various pharmacological interventions on
anthropometric parameters
The high fat diet treatment for 10 weeks caused a sig-
nificant (p < 0.05) increase in % body wt., BMI, Lee index,
liver wt., wt. of fat depots and feed intake (kcal), and de-
crease in feed intake (g), as compared to normal control
rats. Treatment with B. ceiba 100, 200 and 400 mg/kg
and gemfibrozil 50 mg/kg produced significant (p < 0.05)
attenuation of these changes caused due to chronic
HFD, as compared to HFD control. The effect producedFigure 2 Effect of various pharmacological interventions on feed inta
a = p < 0.05 vs NC, b = p < 0.05 vs HFD control, c = p < 0.05 vs Gem.5by B. ceiba 200 and 400 mg/kg was significant greater
(p < 0.05), as compared to Gem.50, in all these parameters
except % body wt. and feed intake (g and kcal) (Figures 1,
2 and 3) (Table 1).Effect of various pharmacological interventions on serum
biochemical parameters
The high fat diet treatment for 10 weeks caused a sig-
nificant (p < 0.05) increase in serum glucose, triglyceride,
LDL, VLDL, total cholesterol, free fatty acid, ALT, AST,
and decrease in HDL levels, as compared to rats fed on
standard chow diet. Treatment with B. ceiba extract in
three doses, and Gem.50 significantly (p < 0.05) attenu-
ated the increase in the levels of these serum markers, as
compared to HFD control. The effect produced by B.
ceiba 400 mg/kg was significantly greater than that of
Gem-50, in all the parameters (Figure 4) (Table 2).ke (g/100 g body wt); Results were expressed as mean ± SD;
0 on respective week.
Figure 3 Effect of various pharmacological interventions on feed intake (Kcal); Results were expressed as mean ± SD; a = p < 0 .05 vs
NC, b = p < 0.05 vs HFD control, c = p < 0.05 vs Gem.50 on respective week.
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biochemical markers
HFD treatment for 10 weeks in HFD control rats caused
significant (p < 0.05) increase in tissue TBARS, nitrate/
nitrite, and decrease in glutathione levels, as compared
to rats fed on standard chow diet. Treatment with B.
ceiba extract 100, 200 and 400 mg/kg and Gem.50 pro-
duced significant (p < 0.05) attenuation of these toxic
changes produced by HFD in the dose dependent manner,
as compared to HFD control rats. The effect produced by
the plant extract 200 and 400 mg/kg was significantly
greater (p < 0.05) than that produced by Gem.50 in all the
parameters (Table 2).
Effect of various pharmacological interventions on
histology of liver and adipose tissue
High fat diet treatment for 10 weeks produced signifi-
cant changes in hepatic tissue architecture such as micro
& macro vascular steatosis, increased fatty infiltration,
inflammation (over activation of kupffer cells), sinusoidalTable 1 Effect of various pharmacological interventions on an
liver
Anthropometric parameters
Group: NC HFD control B.C. 100
BMI 0.580 ± 0.0397 1.088 ± 0.028a 0.882 ± 0.0
Lee index 303.51 ± 10.94 380.9 ± 4.07a 342.7 ± 2.7
Wt. of fat pads and liver wt. (g/100 g of body wt)
Epididymal 2.13 ± 0.42 4.583 ± 0.36a 3.05 ± 0.64
Mesenteric 1.9 ± 0.11 4.85 ± 0.217a 3.95 ± 0.38
Retroperitoneal 1.8 ± 0.43 5.28 ± 0.25a 3.93 ± 0.19
Total fat pads 5.83 ± 0.612 14.72 ± 0.56a 10.93 ± 1.1
Liver wt. 7.083 ± 0.231 13.30 ± 0.62a 12.98 ± 0.6
Results were expressed as mean ± SD; ap < 0.05 vs NC, bp < 0.05 vs HFD control, cp <dilation, degeneration of central vein and vacuolization,
as compared to normal liver histology. Treatment with
B. ceiba 200 and 400 mg/kg significantly attenuated these
effects of HFD, as compared to HFD control. Moreover,
HFD treatment for 10 weeks produced significant in-
crease in size of adipocytes: epididymal, retroperitoneal
and mesenteric fat depots; as compared to rats fed on
standard chow diet. Treatment with B. ceiba extract 200
and 400 mg/kg and Gem.50 significantly (p < 0.05) de-
creased the size of adipocytes, as compared to HFD con-
trol (Figures 5 and 6).
Discussion
The present study demonstrated the anti-obesity effect
of methanolic extract of Bombax ceiba Linn. against
high fat diet-induced obesity in Wistar rats. Gemfibrozil
is a lipid lowering agent, involved in metabolism of car-
bohydrates and fats, as well as adipose tissue differenti-
ation and thereby prevents HFD induced obesity in
rodents [34], and thus was used as a standard in presentthropometric parameters and weights of fat pads and
B.C. 200 B.C. 400 Gem.50
25b 0.675 ± 0.071b,c 0.0.652 ± 0.054b,c 0.779 ± 0.028b
9b 315.97 ± 15.98b,c 313.015 ± 15.033b,c 332.4 ± 5.63b
b 1.3 ± 0.27b,c 1.28 ± 0.24b,c 2 ± 0.48b
b 2.15 ± 0.41b,c 2.17 ± 0.43b,c 3.1 ± 0.66b
7b 2.13 ± 0.34b,c 2.03 ± 0.4b,c 3.23 ± 0.85b
5b 5.58 ± 0.96b,c 5.48 ± 1.03b,c 8.3 ± 1.93b
4 7.48 ± 0.42b,c 7.47 ± 0.52b,c 12.88 ± 0.96
0.05 vs Gem.50.
Figure 4 Effect of various pharmacological interventions on free fatty acids; Results were expressed as mean ± SD; a = p < 0.05 vs NC,
b = p < 0.05 vs HFD control, c = p < 0.05 vs Gem.50.
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anolic or hydro-alcoholic extract has marked affinity for
the active phytoconstituents of B. ceiba. Hence, the me-
thanolic extract was prepared using soxhlet extractor.
Characterization of B. ceiba extract was done in terms of
phytochemical screening which signifies the presence of
alkaloids, glycosides (cardiac-, saponin- glycosides), tan-
nins, terpenoids, steroids and flavonoids in extract. The
plant extract may be standardized for the presence of ac-
tive phytochemical leads through modern analytical
tools: HPLC or HPTLC in future endeavors. The acute
toxicity study as per OECD guidelines derives the safe
use of medicinal agent and its effects on physiological
processes inside the body. Safety assessment is preferred
to start with the assessment of biological effects of any
bioactive agent. In acute toxicity study, the B. ceibaTable 2 Effect of various pharmacological interventions on se
Serum biochemical parameters
Group: NC HFD control B.C. 10
Glucose (mg/dl) 93.65 ± 13.46 202.25 ± 4.16a 177.77
TG (mg/dl) 78.9 ± 11.7 195.54 ± 10.63a 138.94
TC (mg/dl) 57.9 ± 4.8 343.42 ± 15.54a 169.889
LDL (mg/dl) 8.99 ± 5.42 289.76 ± 15.2a 120.83
VLDL (mg/dl) 15.78 ± 2.3 39.11 ± 2.12a 27.79 ±
HDL (mg/dl) 33.13 ± 5.5 14.55 ± 1.9a 21.28 ±
ALT (IU/L) 50.75 ± 6.6 153.26 ± 7.35a 94.28 ±
AST (IU/L) 66.4 ± 6.7 160.83 ± 6.56a 107.86
Tissue biochemical parameters
TBARS 0.6 ± 0.31 4.93 ± 0.64a 3.9 ± 0.
Nitrite/nitrate 0.74 ± 0.4 2.6 ± 0.1a 1.63 ± 0
Glutathione 2.05 ± 0.25 0.19 ± 0.8a 0.42 ± 0
Results were expressed as mean ± SD; ap < 0.05 vs NC, bp < 0.05 vs HFD control, cp <extract was found to be safe and did not reveal any bio-
logical defect and mortality in rodents.
High fat diet induced obesity is a commonly used
model for experimental obesity and closely resembles
with the symptoms of obesity in humans. HFD induced
obesity is characterized by dyslipidemia, hyperglycemia
and insulin resistance, increased fat accumulation, im-
paired glucose metabolism, distinctive visceral adiposity,
hyperinsulinemia and hepatic steatosis in rodents [35,36].
In present study, high fat diet treatment for 10 weeks pro-
duced experimental obesity as evidenced by increased
body weight, feed intake (Kcal), wt. of all fat depots, body
mass index, Lee index, and decreased feed intake (g).
Treatment with different doses of B. ceiba extract and
standard drug (gemfibrozil) caused significant attenuation
in these changes produced by HFD treatment. This effectrum and tissue biochemical parameters
0 B.C. 200 B.C. 400 Gem.50
± 14.1b 95.8 ± 9.42b,c 90.8 ± 6.83b,c 100.3 ± 5.97b
± 5.8b 114.9 ± 11.75b,c 98.7 ± 7.83b,c 128.4 ± 15.3b
± 9.81b 95 ± 6.1b,c 93.12 ± 7.9b,c 94.93 ± 7.3b
± 8.95b 26.45 ± 5.65b,c 13 ± 4.36b,c 15.1 ± 6.9b
1.17b 22.98 ± 2.4b,c 19.74 ± 1.6b,c 25.7 ± 3.1b
5.84b 45.57 ± 8.4b,c 60.37 ± 3.1b,c 54.14 ± 5.1b
5.65b 67.9 ± 4.9b,c 50.8 ± 4.9b,c 71.8 ± 4.64b
± 9.6b 65.38 ± 7.1b,c 50.25 ± 5.1b,c 87.5 ± 12.4b
77b 1.83 ± 0.7b,c 1.53 ± 0.7b,c 4.03 ± 0.71b
.04b 0.98 ± 0.1b,c 0.89 ± 0.69b,c 1.61 ± 0.02b
.07b 1.8 ± 0.21b,c 1.99 ± 0.16b,c 0.55 ± 0.11b
0.05 vs Gem.50.
Figure 5 Effect of various pharmacological interventions on histology of adipose tissues; (A) NC, (B) HFD, (C) B.C. 100, (D) B.C. 200,
(E) B.C. 400 and (F) Gem.50.
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responsible for excessive fat accumulation, dyslipidemia and
weight gain, possibly by increasing leptin sensitivity, pro-
viding anorexic effect, and increasing energy expenditure.
Lipogenesis up-regulation in HFD induced experimental
obesity leads to elevated serum lipids [37] and decreased
HDL levels in obese rats [36]. Further, it also produces
hyperglycemia. The Free fatty acid level is reported to be
increased during HFD induction [38]. It further caused
liver damage and the increased level of hepatic serum
markers like ALT and AST [39]. In present study, these
serum markers have been modulated with chronic induc-
tion of HFD for 10 weeks as the markers of hyperlipid-
emia, dyslipidemia, hyperglycemia, and liver toxicity. On
treatment with three consecutive doses of B. ceiba extract
and gemfibrozil significantly reversed the effects of HFD
treatment on these serum parameters. This may be due to
the inactivation of acetyl-coA carboxylase (ACC), as a re-
sult of AMPK activation that mediates thermogenesis and
FAS inhibition [15], which further inhibit the proximal
and rate limiting steps of fatty acid oxidation [40]. This
may derive the efficacy of B. ceiba’s to reduce circulating
lipids, free fatty acids and thereby prevent fatty liver [41].Figure 6 Effect of various pharmacological interventions on histology
(E) B.C. 400 and (F) Gem.50.The increased fatty acid levels in chronically HFD fed
rats is a characteristic marker caused due to the dysregu-
lation of insulin and leptin signaling and stimulation of
PTP-1B. These processes may be arrested by the admin-
istration of B. ceiba extract in rats and hence corrected
the pharmacological interventions underlying the HFD
induced obesity, as evidenced by the concentration of
fatty acid content in biological fluid. These observations
may be supported by the literatures revealing the efficacy
of flavonoids isolated from B. ceiba extract having FAS
inhibitory activity [15]. Moreover, the Lupeol, a triter-
penoid, is a major constituent of stem bark of B. ceiba
has inhibitory effect on PTP-1B, and thereby prevents
TG synthesis and accumulation of lipids in adipocytes
[16]. On the basis of the observations, it may be hypoth-
esized that there is a possible modulation of FAS and
PTP-1B signaling in protective effect of B. ceiba extract
against HFD induced obesity and this may be due to the
potency and efficacy of reported active phytoconstituents
present in it.
Oxidative stress is greatly increased on the treatment
with high fat diet in the form of enhanced lipid peroxi-
dation reactions and depletion of tissue antioxidant likeof liver tissue; (A) NC, (B) HFD, (C) B.C. 100, (D) B.C. 200,
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sent study, increased TBARS and nitrite/nitrate, and de-
creased GSH levels confirm the role of oxidative and
nitrostative stresses. Treatment with B. ceiba extract 100,
200 and 400 mg/kg significantly attenuated these HFD in-
duced oxidative/nitrosative stress, and this effect was
more pronounced, in comparison to standard drug: gemfi-
brozil. Moreover, another report documented the free rad-
ical scavenging property of B. ceiba [13]. Therefore, the
anti-oxidative efficacy of B. ceiba may contribute for the
amelioration of experimental obesity and hepatic insuffi-
ciencies in rats. In most of the pharmacological assess-
ments, the biological efficacy of B. ceiba extract was more
pronounced as compared to the standard drug: Gemfibro-
zil. These findings may infer that the methanolic extract
of B. ceiba contain active phytoconstituents in higher
concentration or acting synergistically to attain potent
biological efficacy which was comparable to that of
gemfibrozil. The future studies may lend support for the
biological potency of isolated active phytoconstituentss
like Lupeol, Shamimin etc of B. ceiba in sub-maximal
therapeutic dosage and their comparative safe evalu-
ation with reported lipid lowering agent. The findings of
present investigation signifies the use of low dose of ac-
tive phytoconstituent isolated from B. ceiba as much ef-
fective and may be devoid of any toxic effect on chronic
administration in comparison to the reported lipid low-
ering agent.
Hepatic steatosis is a common consequence of obesity,
and its prevalence [39] has been further characterized
with hepatic fat accumulation and increase in size and
wt of adipose masses in the body [42]. By increased liver
steatosis, fatty infiltration, inflammation through Kupffer
cell activation and size of adipose tissues epididymal,
peritoneal, mesenteric fat depots and histological charac-
teristics in present study as also observed in histological
imagining. Various doses of B. ceiba and standard drug
significantly reversed the effect of HFD on liver adipose
tissues and liver steatosis, liver weight and adipose tissue
size was increased during HFD treatment. Moreover ex-
tent of tissue architecture damage due to chronic HFD
treatment was prevented by B. ceiba ext. effectively.
Therefore, in present study, the observed decrease in
free fatty acid level may be due to the inhibition of FAS
activity and TG synthesis, and PTP-1B activity. The anti-
oxidant effect may also contribute to the anti-obesity po-
tential of Bombax ceiba Linn. in Wistar rats.Conclusion
The results obtained in present study may conclude that
the extract of stem bark of Bombax ceiba Linn. has sig-
nificant anti-obesity potential against HFD induced ex-
perimental obesity, possibly due to modulation of FASand PTP-1B signaling in Wistar rats due to the presence
of active flavanoids and lupeol respectively.
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